Related references
Note: Only part of the references are listed.Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial
Yi-Long Wu et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Atezolizumab in patients with advanced non -small cell lung cancer and history of asymptomatic, treated brain metastases: Exploratory analyses of the phase III OAK study
Shirish M. Gadgeel et al.
LUNG CANCER (2019)
Cost-effectiveness of second-line atezolizumab in Canada for advanced non-small cell lung cancer (NSCLC)
Umang Ondhia et al.
JOURNAL OF MEDICAL ECONOMICS (2019)
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
Tony S. K. Mok et al.
LANCET (2019)
First-line atezolizumab in addition to bevacizumab plus chemotherapy for metastatic, nonsquamous non-small cell lung cancer: A United States-based cost-effectiveness analysis
XiaoMin Wan et al.
CANCER (2019)
Cost-effectiveness analysis of pembrolizumab monotherapy and chemotherapy in the non-small-cell lung cancer with different PD-L1 tumor proportion scores
Kexun Zhou et al.
LUNG CANCER (2019)
Cost-effectiveness of pembrolizumab in combination with chemotherapy versus chemotherapy and pembrolizumab monotherapy in the first-line treatment of squamous non-small-cell lung cancer in the US
Ralph P. Insinga et al.
CURRENT MEDICAL RESEARCH AND OPINION (2019)
Cost-effectiveness of pembrolizumab versus chemotherapy as first-line treatment in PD-L1-positive advanced non-small-cell lung cancer in the USA
Min Huang et al.
IMMUNOTHERAPY (2019)
Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (> 50%) metastatic squamous and non-squamous non-small cell lung cancer in France
Christos Chouaid et al.
LUNG CANCER (2019)
Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment in locally advanced or metastatic non-small cell lung cancer with PD-L1 tumor proportion score 1% or greater
Longjiang She et al.
LUNG CANCER (2019)
Cost-effectiveness analysis of first-line pembrolizumab treatment for PD-L1 positive, non-small cell lung cancer in China
Weiting Liao et al.
JOURNAL OF MEDICAL ECONOMICS (2019)
Modelled Economic Evaluation of Nivolumab for the Treatment of Second-Line Advanced or Metastatic Squamous Non-Small-Cell Lung Cancer in Australia Using Both Partition Survival and Markov Models
Lan Gao et al.
APPLIED HEALTH ECONOMICS AND HEALTH POLICY (2019)
Cost-effectiveness analysis of pembrolizumab plus chemotherapy for previously untreated metastatic non-small cell lung cancer in the USA
Xiaohui Zeng et al.
BMJ OPEN (2019)
Cost-effectiveness of Atezolizumab Combination Therapy for First-Line Treatment of Metastatic Nonsquamous Non-Small Cell Lung Cancer in the United States
Steven D. Criss et al.
JAMA NETWORK OPEN (2019)
Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): Moving from targeted therapy to immunotherapy
Lais Osmani et al.
SEMINARS IN CANCER BIOLOGY (2018)
First-line pembrolizumab in PD-L1 positive non-small-cell lung cancer: A cost-effectiveness analysis from the UK health care perspective
Xiaohan Hu et al.
LUNG CANCER (2018)
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
M. A. Socinski et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer
L. Gandhi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Cost-effectiveness of pembrolizumab as first-line therapy for advanced non-small cell lung cancer
Mina Georgieva et al.
LUNG CANCER (2018)
Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer
L. Paz-Ares et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
PD1/PDL1 inhibitors for the treatment of advanced urothelial bladder cancer
David D. Stenehjem et al.
ONCOTARGETS AND THERAPY (2018)
Cost-effectiveness of pembrolizumab in combination with chemotherapy in the 1st line treatment of non-squamous NSCLC in the US
Ralph P. Insinga et al.
JOURNAL OF MEDICAL ECONOMICS (2018)
Cost-effectiveness of pembrolizumab versus docetaxel for the treatment of previously treated PD-L1 positive advanced NSCLC patients in the United States
Min Huang et al.
JOURNAL OF MEDICAL ECONOMICS (2017)
Cost Effectiveness of Pembrolizumab vs. Standard-of-Care Chemotherapy as First-Line Treatment for Metastatic NSCLC that Expresses High Levels of PD-L1 in the United States
Min Huang et al.
PHARMACOECONOMICS (2017)
Immunotherapy for Non-small-cell Lung Cancer: Current Status and Future Obstacles
Ju Hwan Cho
IMMUNE NETWORK (2017)
A Cost-Effectiveness Analysis of Nivolumab versus Docetaxel for Advanced Nonsquamous NSCLC Including PD-L1 Testing
Klazien Matter-Walstra et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
Roy S. Herbst et al.
LANCET (2016)
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Martin Reck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Economic evaluation of nivolumab for the treatment of second-line advanced squamous NSCLC in Canada: a comparison of modeling approaches to estimate and extrapolate survival outcomes
Ron Goeree et al.
JOURNAL OF MEDICAL ECONOMICS (2016)
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer
Julie Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
H. Borghaei et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Acquired resistance to TKIs in solid tumours: learning from lung cancer
D. Ross Camidge et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2014)
CONSOLIDATED HEALTH ECONOMIC EVALUATION REPORTING STANDARDS (CHEERS) STATEMENT
Don Husereau et al.
INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE (2013)
Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship
Julian R. Molina et al.
MAYO CLINIC PROCEEDINGS (2012)
The quality of reporting might not reflect the quality of the study: implications for undertaking and appraising a systematic review
Chris Littlewood et al.
JOURNAL OF MANUAL & MANIPULATIVE THERAPY (2012)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
Share Paper
